Clinical Trial Update: Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ERCP-RFA followed by sequential therapy with envafolimab and surufatinib for unresectable biliary tract cancer. The study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Envafolimab (envafolimab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Unresectable Biliary Tract Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING